Total Payments
$264,638
2024 Payments
$18,829
Companies
19
Transactions
212
Medicare Patients
204
Medicare Billing
$23,202
Payment Breakdown by Category
Other$161,398 (61.0%)
Consulting$47,147 (17.8%)
Travel$36,906 (13.9%)
Research$12,783 (4.8%)
Food & Beverage$6,190 (2.3%)
Education$215.33 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $161,119 | 51 | 60.9% |
| Consulting Fee | $47,147 | 21 | 17.8% |
| Travel and Lodging | $36,906 | 63 | 13.9% |
| Unspecified | $12,783 | 13 | 4.8% |
| Food and Beverage | $6,190 | 61 | 2.3% |
| Entertainment | $279.05 | 1 | 0.1% |
| Education | $215.33 | 2 | 0.1% |
Payments by Type
General
$251,855
199 transactions
Research
$12,783
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $137,054 | 93 | $0 (2022) |
| F. Hoffmann-La Roche AG | $51,681 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $50,236 | 41 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,730 | 4 | $0 (2024) |
| Endomagnetics Ltd | $5,469 | 9 | $0 (2024) |
| GENZYME CORPORATION | $4,212 | 1 | $0 (2022) |
| TerSera Therapeutics LLC | $2,619 | 1 | $0 (2022) |
| GE HEALTHCARE | $2,372 | 3 | $0 (2024) |
| Genentech, Inc. | $1,043 | 3 | $0 (2022) |
| Puma Biotechnology, Inc. | $1,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,829 | 15 | Merck Sharp & Dohme LLC ($10,190) |
| 2023 | $17,181 | 21 | Merck Sharp & Dohme LLC ($13,303) |
| 2022 | $47,273 | 33 | Merck Sharp & Dohme LLC ($20,993) |
| 2021 | $10,235 | 13 | Genentech USA, Inc. ($6,653) |
| 2020 | $21,015 | 18 | Genentech USA, Inc. ($11,752) |
| 2019 | $48,088 | 49 | Genentech USA, Inc. ($34,631) |
| 2018 | $35,836 | 23 | Genentech USA, Inc. ($18,007) |
| 2017 | $66,181 | 40 | Genentech USA, Inc. ($53,865) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $2,159.82 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 07/17/2024 | GE HEALTHCARE | Cerianna (Drug) | Consulting Fee | Cash or cash equivalent | $2,124.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 07/17/2024 | GE HEALTHCARE | Cerianna (Drug) | Consulting Fee | Cash or cash equivalent | $177.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $1,245.89 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $108.99 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $71.13 | General |
| 04/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $3,262.50 | General |
| Category: Oncology | ||||||
| 04/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2024 | Provepharm Inc. | LYMZUL (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: MARKER DYE | ||||||
| 03/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $119.96 | General |
| Category: ONCOLOGY | ||||||
| 02/10/2024 | Endomagnetics Ltd | Magseed (Device), Magtrace | Food and Beverage | Cash or cash equivalent | $62.48 | General |
| Category: Surgical Oncology | ||||||
| 02/09/2024 | Endomagnetics Ltd | Magseed (Device), Magtrace | Food and Beverage | Cash or cash equivalent | $182.67 | General |
| Category: Surgical Oncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $1,662.62 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $542.55 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 12/20/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $548.10 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $183.47 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $66.75 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $37.50 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| T DM1 high risk EBC pts with residual inv disease | F. Hoffmann-La Roche AG | $5,587 | 4 |
| A Randomized, Multicenter, Open-Label Phase III Study to Evaluate Efficacy and Safety of Trastuzumab Emtansine vs Trastuzumab as Adjuvant Therapy for Patients with HER2 Primary Breast Cancer with Residual Tumor Present Pathologically in Breast or Axillary Lymph Nodes Following Preoperative Therapy | F. Hoffmann-La Roche AG | $4,745 | 6 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY | F. Hoffmann-La Roche AG | $2,450 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 37 | 49 | $11,515 | $2,242 |
| 2022 | 2 | 55 | 62 | $17,810 | $4,049 |
| 2021 | 1 | 31 | 34 | $7,480 | $1,719 |
| 2020 | 5 | 81 | 86 | $67,796 | $15,193 |
Total Patients
204
Total Services
231
Medicare Billing
$23,202
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 37 | 49 | $11,515 | $2,242 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 40 | 47 | $10,340 | $2,411 | 23.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 15 | 15 | $7,470 | $1,638 | 21.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 34 | $7,480 | $1,719 | 23.0% |
| 19301 | Partial removal of breast | Facility | 2020 | 12 | 15 | $31,170 | $8,547 | 27.4% |
| 38525 | Biopsy or removal of lymph nodes of under the arm, open procedure | Facility | 2020 | 12 | 12 | $16,716 | $2,265 | 13.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 15 | 15 | $7,470 | $1,605 | 21.5% |
| 38900 | Lymph node imaging during surgery | Facility | 2020 | 12 | 12 | $5,400 | $1,465 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 32 | $7,040 | $1,311 | 18.6% |
About Dr. Eleftherios Mamounas, MD
Dr. Eleftherios Mamounas, MD is a Surgery healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174580492.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eleftherios Mamounas, MD has received a total of $264,638 in payments from pharmaceutical and medical device companies, with $18,829 received in 2024. These payments were reported across 212 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($161,119).
As a Medicare-enrolled provider, Mamounas has provided services to 204 Medicare beneficiaries, totaling 231 services with total Medicare billing of $23,202. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgery
- Other Specialties Surgical Oncology, Surgery
- Location Orlando, FL
- Active Since 04/28/2006
- Last Updated 05/13/2024
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1174580492
Products in Payments
- Perjeta (Biological) $96,660
- Kadcyla (Biological) $55,067
- KEYTRUDA (Biological) $36,545
- Herceptin (Biological) $29,604
- KISQALI (Drug) $3,263
- Zoladex (Drug) $2,619
- Cerianna (Drug) $2,301
- Phesgo (Biological) $1,160
- NERLYNX (Drug) $1,000
- Enhertu (Drug) $760.51
- LYMZUL (Drug) $600.00
- IMFINZI (Drug) $537.00
- Magseed (Device) $481.51
- SURG - NEPTUNE (Device) $148.85
- Trodelvy (Drug) $91.49
- LYNPARZA (Biological) $10.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in Orlando
Dr. Scott Silvestry, Md, MD
Surgery — Payments: $777,054
Surgery $777,054
Juan Escalon, Md, MD
Surgery — Payments: $312,626
Surgery $312,626
Dr. Hany Takla, M.d, Mrcs, M.D, MRCS
Surgery — Payments: $214,977
Surgery $214,977
Gustavo Bello Vincentelli, M.d, M.D
Surgery — Payments: $110,915
Surgery $110,915
Imran Siddiqui, M.d, M.D
Surgery — Payments: $44,576
Surgery $44,576
Scott Bloom, M.d, M.D
Surgery — Payments: $41,946
Surgery $41,946